Clinical Focus

  • Sleep Medicine

Academic Appointments

Professional Education

  • Doctor of Medicine, Unlisted School (2014)
  • Board Certification: American Board of Internal Medicine, Sleep Medicine (2023)
  • Fellowship: Stanford University Sleep Medicine Fellowship (2023) CA
  • Board Certification: American Board of Internal Medicine, Pulmonary Disease (2022)
  • Fellowship: Corpus Christi Medical Center (2022) TX
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2020)
  • Residency: Icahn School of Medicine at Mount Sinai (2020) NY
  • Medical Education: Faculty of Medicine Siriraj Hospital Mahidol University (2014) Thailand

Stanford Advisors

Contact

  • Academic
    pahnwatt@stanford.edu
    University - Scholar Department: Psychiatry and Behavioral Sciences Position: Postdoctoral Scholar
    University - Staff Department: Psych/Sleep Medicine Position: Clinical Instructor
  • Clinical (Primary)  430 Broadway St Rm 302 Pavilion C 3rd Fl MC 6343 Redwood City, CA 94063 (650) 724-9900 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5480

All Publications

  • Carbon ion radiation therapy in prostate cancer: The importance of dosage. World journal of radiology Treechairusame, T., Taweesedt, P. T. 2024; 16 (11): 696-699

    Abstract

    In this article, we comment on the article by Ono et al. We focus specifically on the carbon ion radiotherapy studies and the method to calculate the dosing schedule. While photon hypofractionated radiotherapy in prostate cancer has demonstrated improvement in tumor control with reduced gastrointestinal toxicity compared to conventional radiotherapy, carbon ion radiotherapy (CIRT) offers additional physical and biological advantages. Recent findings, including those from Ono et al, have established new dose constraints of CIRT for prostate cancer treatment and risk factors for rectal bleeding. Due to limited data on CIRT dosing, this study underscores the need for more research to refine dose calculation methods and better understand their effects on clinical outcomes.

    View details for DOI 10.4329/wjr.v16.i11.696

    View details for PubMedID 39635316

    View details for PubMedCentralID PMC11612798

  • Impact of sleep on gastrointestinal cancer. World journal of clinical oncology Lo, J., Taweesedt, P. T., Kawai, M. 2024; 15 (6): 677-683

    Abstract

    Sleep problems have become a significant public health concern, affecting a large portion of the global population and have been linked to increased morbidity and mortality. The incidence of gastrointestinal (GI) cancers continues to rise, posing a substantial burden on healthcare systems worldwide. This editorial aims to delve into the impact of sleep on GI cancers, including esophageal, gastric, colorectal, hepatobiliary, and pancreatic cancer. Recent literature investigating the potential connections between GI cancers and sleep was reviewed. We considered aspects such as sleep duration, sleep disorders, and circadian rhythmicity, in order to explore the underlying mechanisms that can contribute to the development of GI cancers and propose avenues for future research.

    View details for DOI 10.5306/wjco.v15.i6.677

    View details for PubMedID 38946837

    View details for PubMedCentralID PMC11212604

  • Impact of Antifibrotic Treatment on Postoperative Complications in Patients with Interstitial Lung Diseases Undergoing Lung Transplantation: A Systematic Review and Meta-Analysis. Journal of clinical medicine Taweesedt, P., Lertjitbanjong, P., Eksombatchai, D., Charoenpong, P., Moua, T., Thongprayoon, C., Tangpanithandee, S., Petnak, T. 2023; 12 (2)

    Abstract

    Antifibrotic treatment has been approved for reducing disease progression in fibrotic interstitial lung disease (ILD). As a result of increased bleeding risk, some experts suggest cessation of antifibrotics prior to lung transplantation (LT). However, extensive knowledge regarding the impact of antifibrotic treatment on postoperative complications remains unclear. We performed a comprehensive search of several databases from their inception through to 30 September 2021. Original studies were included in the final analysis if they compared postoperative complications, including surgical wound dehiscence, anastomosis complication, bleeding complications, and primary graft dysfunction, between those with and without antifibrotic treatment undergoing LT. Of 563 retrieved studies, 6 studies were included in the final analysis. A total of 543 ILD patients completing LT were included, with 161 patients continuing antifibrotic treatment up to the time of LT and 382 without prior treatment. Antifibrotic treatment was not significantly associated with surgical wound dehiscence (RR 1.05; 95% CI, 0.31-3.60; I2 = 0%), anastomotic complications (RR 0.88; 95% CI, 0.37-2.12; I2 = 31%), bleeding complications (RR 0.76; 95% CI, 0.33-1.76; I2 = 0%), or primary graft dysfunction (RR 0.87; 95% CI, 0.59-1.29; I2 = 0%). Finally, continuing antifibrotic treatment prior to LT was not significantly associated with decreased 1-year mortality (RR 0.80; 95% CI, 0.41-1.58; I2 = 0%). Our study suggests a similar risk of postoperative complications in ILD patients undergoing LT who received antifibrotic treatment compared to those not on antifibrotic therapy.

    View details for DOI 10.3390/jcm12020655

    View details for PubMedID 36675583

  • Obstructive Sleep Apnea: New Perspective. Medicina (Kaunas, Lithuania) Surani, S., Taweesedt, P. 2022; 59 (1)

    Abstract

    Obstructive sleep apnea (OSA) is one of the most common sleep disorders globally [...].

    View details for DOI 10.3390/medicina59010075

    View details for PubMedID 36676699